Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Generate Investment Management Ltd

Generate Investment Management Ltd trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 74.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 5,767 shares of the biopharmaceutical company’s stock after selling 17,233 shares during the quarter. Generate Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $4,373,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Orbimed Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $11,358,000. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $5,682,636,000. Contravisory Investment Management Inc. purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $6,327,000. Oxbow Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $3,342,000. Finally, Deutsche Bank AG purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $323,249,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on REGN shares. Truist Financial lifted their price objective on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Sanford C. Bernstein upped their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a “market perform” rating in a report on Friday, August 14th. BMO Capital Markets boosted their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. Finally, Raymond James Financial increased their price objective on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $834.24.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the sale, the executive vice president owned 12,003 shares of the company’s stock, valued at $10,291,252.17. This represents a 8.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,946 shares of company stock valued at $3,302,458 over the last three months. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $22.82 during trading hours on Wednesday, reaching $775.94. 332,608 shares of the company’s stock were exchanged, compared to its average volume of 819,578. The stock has a market capitalization of $79.89 billion, a P/E ratio of 19.17, a P/E/G ratio of 1.38 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $564.00 and a fifty-two week high of $859.34. The business has a fifty day moving average price of $790.91 and a 200-day moving average price of $720.73. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the prior year, the firm earned $12.81 EPS. The business’s revenue was up 16.7% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.